EXSCEL TRIAL RESULTS 2019

The EXenatide Study of Cardiovascular Event Lowering (EXSCEL) was a randomized, placebo-controlled, global pragmatic clinical trial designed to assess the effect of subcutaneous once-weekly GLP-1 RA exenatide (EQW) 2 mg on cardiovascular outcomes in 14,752 participants with type 2 diabetes mellitus...